Qing et al. reply—The conclusion by Qiu et al. that HEp-2 and A431 cells do not express FGFR is wrong. The Muggeridge et al . report7 they quote clearly shows that the FGFR number per cell is approximately 300.
There are few details of how Qiu et al. generated the data presented in their table. The remarkably high multiplicity of infection used in these experiments is not standard, and it is difficult to reconcile their 60% transduction rate for HeLa cells when others have reported that AAV vectors do not transduce these cells well because of the rate-limiting viral second-strand DNA synthesis11,12. Transduction efficiencies of 40% for HEp-2 and 10% for A431, respectively, are cited as proof that these cells can be transduced in the absence of FGFR expression. Yet, as stated above, these cells do indeed express FGFR (ref. 7). Thus, it seems that the analysis of FGFR by Qiu et al. using flow cytometry with a monoclonal antibody is inadequate to draw such a conclusion.
We have compared the transduction efficiency of a recombinant AAV-lacZ vector (4 × 103 particles/cell) and found transduction efficiencies in HeLa and 293 cells of approximately 4% and 20%, respectively, and <1% in A431 cells which are known to efficiently bind AAV (ref. 13). The lack of trangene expression in A431 cells has previously been reported to be due to very high levels of expression of the epidermal growth factor receptor (EGFR) protein tyrosine kinase known to limit the viral second-strand DNA synthesis13. The observed lack of transduction of M07e cells, which we showed do express FGFR (ref. 1), has previously been shown to be due to lack of expression of heparan sulfate proteoglycan14 (HSPG), a co-receptor of AAV. The absolute requirement for the deliberate expression of both HSPG and FGFR1 in Raji cells, which are known to lack expression of both of these genes15, to render these cells permissive for AAV infection, strongly supports our contention that both HSPG and FGFR1 serve as co-receptors for AAV. Of course, other co-receptors may be used in other cells.
References
Qing, K.Y. et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Med. 5, 71–77 (1999).
Summerford, C., Bartlett, J.S. & Samulski, R.J. aVb5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nature Med. 5, 78 –81 (1999).
Coughlin, S.R., Barr, P.J., Cousens, L.S., Fretto, L.J. & Williams, L.T. Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J. Biol. Chem 263, 988–993 ( 1988).
Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P. & Ornitz, J.D. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64, 841– 848 (1991).
WuDunn, D. & Spear, P.G. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63, 52–58 (1989).
Kaner, R. J. et al. Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type 1. Science 248, 1410–1413 (1990).
Muggeridge et al. Herpes simplex virus infection can occur without involvement of the fibroblast growth factor receptor. J. Virol. 66, 824 –830 (1992).
Mizukami, H., Young, N. & Brown, K.E. Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology 217, 124–130 (1996).
Qiu, J. & Brown, K.E. Virology (in the press).
Wicham, T.J., Mathias, P., Cheresh, D.A. & Nemerow, G.R. Integrins αVβ3 and αVβ5 promote adenovirus internalization but not virus attachmemt. Cell 73, 309– 319 (1993).
Fisher K.J. et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading strand synthesis. J. Virol. 70, 520–532 (1996).
Ferrari, F.K., Samulski, T., Shenk, T. & Samulski, R.J. Second-strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227–3234 (1996).
Mah, C. et al. Adeno-associated virus 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J. Virol. 72, 9835–9843 ( 1998).
Bartlett, J.S., & Samulski, R.J. Fluorescent viral vectors: A new technique for the pharmacological analysis of gene therapy. Nature Med. 4, 635–637 (1998).
Kiefer, M.C. et al. Ligand-affinity cloning and structure of a call surface heparansulfate proteoglycan that binds basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 87, 6985–6989 (1990).
Chong, L.D. & Rose, J.K. Membrane association of functional vesicular stomatitis virus matrix protein in vivo. J. Virol. 67, 407–414 ( 1993).
Hennache, B. & Boulanger, P. Biochemical study of KB-cell receptor for Adenovirus. Biochem. J. 166, 237– 247 (1977).
Wicham, T.J., Filardo, E.J., Cheresh, D.A. & Nemerow, G.R. Integrin αVβ5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol. 127, 257 –264 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Qing, K., Hansen, J. & Srivastava, A. Adeno-associated virus 2 co-receptors?-first reply. Nat Med 5, 468 (1999). https://doi.org/10.1038/8526
Issue Date:
DOI: https://doi.org/10.1038/8526
This article is cited by
-
Gene Transfer Properties and Structural Modeling of Human Stem Cell-derived AAV
Molecular Therapy (2014)
-
A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype
Virology Journal (2013)
-
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Molecular Therapy (2012)
-
Directing Integrin-linked Endocytosis of Recombinant AAV Enhances Productive FAK-dependent Transduction
Molecular Therapy (2012)
-
Cell Membrane–associated Heparan Sulfate Is a Receptor for Prototype Foamy Virus in Human, Monkey, and Rodent Cells
Molecular Therapy (2012)
